Paper23116010
Multivalent ligand: design principle for targeted therapeutic delivery approach.
Chittasupho C. Ther Deliv, 2012. Cited by 61 papers, by iCite.
Cite this record
ConductScience Library. Multivalent ligand: design principle for targeted therapeutic delivery approach. Papers, record 23116010. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23116010
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Drug Delivery Systems | Major topic |
| Drug Design | Major topic |
| Animals | |
| Binding Sites | |
| Humans | |
| Ligands | |
| Thermodynamics |
Source PubMed
Cited by27
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 61 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42711843 | Dual-Target Nectin-4/FAP Heterobivalent Probe 68Ga/177Lu-FZ-NF-1 for Triple-Negative Breast Cancer: Preclinical Theranostic Evaluation and First-in-Human Translation. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/42711843 | PubMed |
| 41550162 | Targeted drug conjugates in cancer therapy: Challenges and opportunities. | Pharm Sci Adv | 2024 | https://conductscience.org/library/papers/41550162 | PubMed |
| 39365862 | P2X7 receptors exhibit at least three modes of allosteric antagonism. | Sci Adv | 2024 | https://conductscience.org/library/papers/39365862 | PubMed |
| 39092437 | Affinity enhancement of polo-like kinase 1 polo box domain-binding ligands by a bivalent approach using a covalent kinase-binding component. | RSC Chem Biol | 2024 | https://conductscience.org/library/papers/39092437 | PubMed |
| 38661191 | Multivalent DNAzyme agents for cleaving folded RNA. | Nucleic Acids Res | 2024 | https://conductscience.org/library/papers/38661191 | PubMed |
| 38176714 | Design, Preclinical Evaluation, and Clinical Translation of 68Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma. | J Nucl Med | 2024 | https://conductscience.org/library/papers/38176714 | PubMed |
| 37760428 | Radiolabeled NGR-Based Heterodimers for Angiogenesis Imaging: A Review of Preclinical Studies. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37760428 | PubMed |
| 37181631 | Identification of multidentate tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors that simultaneously access the DNA, protein and catalytic-binding sites by oxime diversification. | RSC Chem Biol | 2023 | https://conductscience.org/library/papers/37181631 | PubMed |
| 37142301 | Clinical Evaluation of 68Ga-FAPI-RGD for Imaging of Fibroblast Activation Protein and Integrin αvβ3 in Various Cancer Types. | J Nucl Med | 2023 | https://conductscience.org/library/papers/37142301 | PubMed |
| 36558148 | Nerve Targeting via Myelin Protein Zero and the Impact of Dimerization on Binding Affinity. | Molecules | 2022 | https://conductscience.org/library/papers/36558148 | PubMed |
| 36128509 | Development of ultra-high affinity bivalent ligands targeting the polo-like kinase 1. | RSC Chem Biol | 2022 | https://conductscience.org/library/papers/36128509 | PubMed |
| 36034180 | Engineered multivalent self-assembled binder protein against SARS-CoV-2 RBD. | Biochem Eng J | 2022 | https://conductscience.org/library/papers/36034180 | PubMed |
| 35942040 | Multivalent ACE2 engineering-A promising pathway for advanced coronavirus nanomedicine development. | Nano Today | 2022 | https://conductscience.org/library/papers/35942040 | PubMed |
| 35589404 | A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor Uptake. | J Nucl Med | 2022 | https://conductscience.org/library/papers/35589404 | PubMed |
| 35439047 | Discovery of unusual dimeric piperazyl cyclopeptides encoded by a Lentzea flaviverrucosa DSM 44664 biosynthetic supercluster. | Proc Natl Acad Sci U S A | 2022 | https://conductscience.org/library/papers/35439047 | PubMed |
| 35013982 | Critical parameters for design and development of multivalent nanoconstructs: recent trends. | Drug Deliv Transl Res | 2022 | https://conductscience.org/library/papers/35013982 | PubMed |
| 34982497 | Significance of Receptor Mobility in Multivalent Binding on Lipid Membranes. | Angew Chem Int Ed Engl | 2022 | https://conductscience.org/library/papers/34982497 | PubMed |
| 34847142 | Avidity observed between a bivalent inhibitor and an enzyme monomer with a single active site. | PLoS One | 2021 | https://conductscience.org/library/papers/34847142 | PubMed |
| 34163656 | Small molecule microarray identifies inhibitors of tyrosyl-DNA phosphodiesterase 1 that simultaneously access the catalytic pocket and two substrate binding sites. | Chem Sci | 2021 | https://conductscience.org/library/papers/34163656 | PubMed |
| 33073549 | Ligand Density Controls C-Type Lectin-Like Molecule-1 Receptor-Specific Uptake of Polymer Nanoparticles. | Adv Biosyst | 2020 | https://conductscience.org/library/papers/33073549 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23116010
GET https://conductscience.org/api/papers/v1/23116010/cited_by?page=2